Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Morris

Showing results (171-180 of 324) with videos related to

Pageof 33
Sort By:
Frontiers in Plant Science|November 19, 2019
Production and Immunogenicity of Soluble Plant-Produced HIV-1 Subtype C Envelope gp140 ImmunogensEmmanuel Margolin, Rosamund Chapman, Ann E Meyers, et al.
Virology|April 11, 2020
Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infectionBongiwe Ndlovu, Kamini Gounder, Daniel Muema, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2014
Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitorsAdriaan E Basson, Soo-Yon Rhee, Chris M Parry, et al.
Plos One|April 17, 2008
Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection studyFrancois van Loggerenberg, Koleka Mlisana, Carolyn Williamson, et al.
Iscience|January 5, 2022
Sequence and functional characterization of a public HIV-specific antibody clonotypeAmyn A Murji, Nagarajan Raju, Juliana S Qin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 13, 2009
Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapyAshraf Coovadia, Gillian Hunt, Elaine J Abrams, et al.
Frontiers in Immunology|July 24, 2019
Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected ChildrenJulia Roider, J Zachary Porterfield, Paul Ogongo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 23, 2011
Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South AfricaJ Nomthandazo Dlamini, Zonghui Hu, Johanna Ledwaba, et al.
Plos Pathogens|April 10, 2018
HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodiesSimone I Richardson, Amy W Chung, Harini Natarajan, et al.
AIDS (London, England)|September 20, 2017
Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responsesCathrine Scheepers, Sudipa Chowdhury, W Shea Wright, et al.
Pageof 33

Showing results (171-180 of 324) with videos related to

Sort By:
Pageof 33
Frontiers in Plant Science|November 19, 2019
Production and Immunogenicity of Soluble Plant-Produced HIV-1 Subtype C Envelope gp140 ImmunogensEmmanuel Margolin, Rosamund Chapman, Ann E Meyers, et al.
Virology|April 11, 2020
Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infectionBongiwe Ndlovu, Kamini Gounder, Daniel Muema, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2014
Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitorsAdriaan E Basson, Soo-Yon Rhee, Chris M Parry, et al.
Plos One|April 17, 2008
Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection studyFrancois van Loggerenberg, Koleka Mlisana, Carolyn Williamson, et al.
Iscience|January 5, 2022
Sequence and functional characterization of a public HIV-specific antibody clonotypeAmyn A Murji, Nagarajan Raju, Juliana S Qin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 13, 2009
Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapyAshraf Coovadia, Gillian Hunt, Elaine J Abrams, et al.
Frontiers in Immunology|July 24, 2019
Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected ChildrenJulia Roider, J Zachary Porterfield, Paul Ogongo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 23, 2011
Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South AfricaJ Nomthandazo Dlamini, Zonghui Hu, Johanna Ledwaba, et al.
Plos Pathogens|April 10, 2018
HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodiesSimone I Richardson, Amy W Chung, Harini Natarajan, et al.
AIDS (London, England)|September 20, 2017
Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responsesCathrine Scheepers, Sudipa Chowdhury, W Shea Wright, et al.
Pageof 33